{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:05:36Z","timestamp":1785423936725,"version":"3.56.0"},"reference-count":23,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>This Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not consistently shown to reduce mortality or improve quality of life based on randomised trials.Inhaled corticosteroids have shown limited benefits for COPD symptoms and exacerbations but increased risks of serious harms. Guidelines recommend limiting ICS to severe COPD and only for repeated exacerbations. Studies show withdrawing ICS can be done safely for stable COPD patients with infrequent exacerbations, especially those with lower eosinophil counts. Provincial, national and international guidelines now recommend limiting ICS prescriptions to severe COPD stages. Long-term ICS use may lead to serious side effects, including pneumonia and fractures. Initial COPD therapy should focus on short-acting bronchodilators, not ICS. Adding long-acting bronchodilators is recommended before considering ICS because of limited benefits and risks of serious harms. For persistent symptoms, long-acting muscarinic antagonists (LAMA) or long-acting beta2 agonists (LABA) are recommended, with the addition of ICS reserved for those with repeated exacerbations and severe COPD. Deprescribing ICS can be considered in clinically stable patients, particularly for those with infrequent exacerbations and mild COPD. When applicable, tapering ICS over several months is advised for patients with elevated eosinophil counts. Overall, the risks of serious harms from ICS typically outweigh their limited benefits for mild COPD patients in primary care.<\/jats:p>","DOI":"10.4102\/phcfm.v16i1.4756","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:50:16Z","timestamp":1734637816000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Minimising inhaled corticosteroids for COPD"],"prefix":"10.4102","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-5432","authenticated-orcid":false,"given":"Benji","family":"Heran","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-4206","authenticated-orcid":false,"given":"Thomas L.","family":"Perry","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-562X","authenticated-orcid":false,"given":"Ken","family":"Bassett","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref0","unstructured":"US Department of Health and Human Services. Smoking cessation. A report of the surgeon general [homepage on the Internet]. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2020 [cited 2024 Sep 19]. Available from: https:\/\/www.hhs.gov\/sites\/default\/files\/2020-cessation-sgr-full-report.pdf"},{"key":"ref1","unstructured":"Therapeutics Initiative. Update of Provincial Academic Detailing Service (PAD) literature review: Inhaled medications for treatment of chronic obstructive pulmonary disease (COPD) [homepage on the Internet]. 2019 [cited 2024 Sep 19]. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/health-drug-coverage\/pharmacare\/2019-02-28_ubc_ti_report_copd.pdf"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Akunne OO, Valoyi VC, Wehmeyer A, Johnson Y, Coetzee R. Implications of the South African National Drug Policy on prescribing patterns: A case study of the Limpopo province. J Pharm Policy Pract. 2023;16:111. https:\/\/doi.org\/10.1186\/s40545-023-00622-4","DOI":"10.1186\/s40545-023-00622-4"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ofori-Asenso R, Brhlikova P, Pollock AM. Prescribing indicators at primary health care centers within the WHO African region: A systematic analysis (1995\u20132015). BMC Public Health. 2016;16:724. https:\/\/doi.org\/10.1186\/s12889-016-3428-8","DOI":"10.1186\/s12889-016-3428-8"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mekonnen BD, Ayalew MZ, Tegegn AA. Rational drug use evaluation based on World Health Organization core drug use indicators in Ethiopia: A systematic review. Drug Healthc Patient Saf. 2021;13:159\u2013170. https:\/\/doi.org\/10.2147\/DHPS.S311926","DOI":"10.2147\/DHPS.S311926"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Awad AI, Ball DE, Eltayeb IB. Improving rational drug use in Africa: The example of Sudan. East Mediterr Health J. 2007;13(5):1202\u20131211. https:\/\/doi.org\/10.26719\/2007.13.5.1202","DOI":"10.26719\/2007.13.5.1202"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ag Ahmed MA, Ravinetto R, Diop K, Buitrago VT, Dujardin C. Evaluation of rational medicines use based on World Health Organization core indicators: A cross-sectional study in five health districts in Mauritania. Integr Pharm Res Pract. 2024:13:17\u201329. https:\/\/doi.org\/10.2147\/IPRP.S447664","DOI":"10.2147\/IPRP.S447664"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chen H, Zheneng-Xu D, Jian S, et al. Association of inhaled corticosteroids with all-cause mortality risk in patients with COPD. A Meta-analysis of 60 randomized controlled trials. Chest. 2023;163(1):100\u2013114. https:\/\/doi.org\/10.1016\/j.chest.2022.07.015","DOI":"10.1016\/j.chest.2022.07.015"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: The case against. Eur Respir J. 2009;34(1):13\u201316. https:\/\/doi.org\/10.1183\/09031936.00190908","DOI":"10.1183\/09031936.00190908"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775\u2013789. https:\/\/doi.org\/10.1056\/NEJMoa063070","DOI":"10.1056\/NEJMoa063070"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med. 2007;146(8):545\u2013555. https:\/\/doi.org\/10.7326\/0003-4819-146-8-200704170-00152","DOI":"10.7326\/0003-4819-146-8-200704170-00152"},{"key":"ref11","unstructured":"BC Provincial Academic Detailing Service. COPD update: Focus on intensifying LABA, LAMA and ICS therapy [homepage on the Internet]. 2017 [cited 2024 Sep 19]. Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/practitioner-pro\/provincial-academic-detailing-service\/copd_update.pdf"},{"key":"ref12","unstructured":"Guidelines and Protocols and Advisory Committee (GPAC). Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and management [homepage on the Internet]. Effective Date: February 22nd, 2017 Revised Date: Medication table updated July 2020 [cited 2024 Sep 19]. Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/bc-guidelines\/copd"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD \u2013 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3(4):210\u2013232. https:\/\/doi.org\/10.1080\/24745332.2019.1668652","DOI":"10.1080\/24745332.2019.1668652"},{"key":"ref14","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2023 [cited 2024 Sep 19]. Available from: https:\/\/goldcopd.org"},{"key":"ref15","unstructured":"Therapeutics Initiative. Analysis of PharmaNet data. Sept 2022 (unpublished)."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Chalmers JD, Tebboth A, Gayle A, et al. Determinants of initial inhaled corticosteroid use in patients with GOLD A\/B COPD: A retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017;27(1):43. https:\/\/doi.org\/10.1038\/s41533-017-0040-z","DOI":"10.1038\/s41533-017-0040-z"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(3):CD010115. https:\/\/doi.org\/10.1002\/14651858.CD010115.pub2","DOI":"10.1002\/14651858.CD010115.pub2"},{"key":"ref18","unstructured":"Therapeutics Initiative. ICS Meta-analysis 2020 (manuscript in preparation for publication)."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Tan J, White J, Walters JAE, Walters EH. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;11:CD011600. https:\/\/doi.org\/10.1002\/14651858.CD011600.pub2","DOI":"10.1002\/14651858.CD011600"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285\u20131294. https:\/\/doi.org\/10.1056\/NEJMoa1407154","DOI":"10.1056\/NEJMoa1407154"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): A randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329\u2013339. https:\/\/doi.org\/10.1164\/rccm.201803-0405OC","DOI":"10.1164\/rccm.201803-0405OC"},{"key":"ref22","unstructured":"Perry T, editor. Therapeutics Letter. Vancouver (BC): Therapeutics Initiative, Letter 145, Minimizing inhaled corticosteroids for COPD; 2023 Oct. PMID: 39432705."}],"container-title":["African Journal of Primary Health Care &amp; Family Medicine"],"original-title":[],"link":[{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4756\/7822","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4756\/7823","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4756\/7824","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4756\/7825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/4756\/7825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:36:44Z","timestamp":1777034204000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/4756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.4102\/phcfm.v16i1.4756","relation":{},"ISSN":["2071-2928","2071-2936"],"issn-type":[{"value":"2071-2928","type":"print"},{"value":"2071-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"a4756"}}